Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Ther Adv Chronic Dis. 2011 Jan 1;2(1):9-23. doi: 10.1177/2040622310382817.
Alzheimer disease (AD) is a progressive neurodegenerative disease which begins with insidious deterioration of higher cognition and progresses to severe dementia. Clinical symptoms typically involve impairment of memory and at least one other cognitive domain. Because of the exponential increase in the incidence of AD with age, the aging population across the world has seen a congruous increase AD, emphasizing the importance of disease altering therapy. Current therapeutics on the market, including cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, provide symptomatic relief but do not alter progression of the disease. Therefore, progress in the areas of prevention and disease modification may be of critical interest. In this review, we summarize novel AD therapeutics that are currently being explored, and also mechanisms of action of specific drugs within the context of current knowledge of AD pathologic pathways.
阿尔茨海默病（AD）是一种进行性神经退行性疾病，始于高级认知功能的隐匿性恶化，并进展为严重痴呆。临床症状通常包括记忆障碍和至少其他一个认知领域的损害。由于 AD 的发病率随年龄呈指数增长，全球老龄化人口中 AD 的发病率相应增加，这强调了改变疾病治疗方法的重要性。目前市场上的治疗方法，包括胆碱酯酶抑制剂和 N-甲基-D-天冬氨酸受体拮抗剂，仅能提供症状缓解，而不能改变疾病的进展。因此，预防和疾病修饰领域的进展可能具有重要意义。在这篇综述中，我们总结了目前正在探索的新型 AD 治疗方法，并根据 AD 病理途径的现有知识，总结了特定药物的作用机制。
